Kisspeptin
KISS1 Gene-Derived Neuropeptide (Metastin)
Mechanism of Action
Endogenous neuropeptide (product of the KISS1 gene) that binds KISS1R (GPR54) on hypothalamic GnRH neurons, triggering pulsatile GnRH release and downstream LH/FSH secretion. Trial data also link kisspeptin administration to modulation of brain regions involved in sexual and romantic-attraction processing.
Key Benefits
- Drives pulsatile GnRH/LH/FSH release — the master switch of the reproductive axis
- Modulated brain regions tied to sexual and facial-attraction processing in an RCT
- Investigated as a therapeutic candidate for hypoactive sexual desire disorder
- Central to research on reproductive-axis disorders (hypogonadotropic hypogonadism, puberty timing)
Dosing Protocol
Far earlier-stage than other hormone-axis peptides in this library — most human data comes from supervised IV-infusion research trials, not SubQ self-administration. Treat self-administered dosing as extrapolated, not validated.
Ideal Candidates
Reproductive endocrinology research; investigational interest for libido/HSDD support. Not an established self-administered protocol.
Side Effects & Safety
Well-tolerated in trial settings (IV infusion); minimal reported adverse effects. Long-term self-administered safety data is essentially absent.
Regulatory Status
RestrictedNo FDA approval, no 503A listing. Human data is limited almost entirely to supervised IV-infusion research trials — not an established self-administered protocol.
Evidence & Citations
Frequently asked
What is Kisspeptin?+
Kisspeptin (KISS1 Gene-Derived Neuropeptide (Metastin)) is a peptide studied for gnrh axis regulation and reproductive hormone signaling. Endogenous neuropeptide (product of the KISS1 gene) that binds KISS1R (GPR54) on hypothalamic GnRH neurons, triggering pulsatile GnRH release and downstream LH/FSH secretion. Trial data also link kisspeptin administration to modulation of brain regions involved in sexual and romantic-attraction processing.
What is the dosing protocol for Kisspeptin?+
Literature commonly references 250 mcg (research protocols) (low) to 500 mcg–1 mg (research protocols) (maintenance) via SubQ (research); IV infusion in clinical trials, on a 4–8 weeks cycle. Educational reference only — a licensed Stackhaus Health provider sets any personalized protocol.
What is the regulatory status of Kisspeptin?+
No FDA approval, no 503A listing. Human data is limited almost entirely to supervised IV-infusion research trials — not an established self-administered protocol.
Where can I access Kisspeptin?+
Research-grade Kisspeptin is available through Stackhaus Research. For a personalized, provider-reviewed protocol, consult a licensed clinician through Stackhaus Health.